Sökning: id:"swepub:oai:DiVA.org:liu-194177" >
Long-term and real-...
-
Hübbert, LailaLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken i Norrköping
(författare)
Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
FRONTIERS MEDIA SA,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-194177
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-194177URI
-
https://doi.org/10.3389/fonc.2023.1095251DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152600025URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:154484692URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BackgroundThe administration of anticancer drugs in females with comorbidity increases the risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), which in turn contributes to cardiovascular disease (CVD). Furthermore, a pathophysiological connection between cancer and cardiovascular disease may exist. ObjectiveTo assess the long-term risks and predictors of CTR-CVT, including clinical hypertension (HT), coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), as well as all-cause mortality in women diagnosed with early breast cancer (BC) and eligible for adjuvant chemotherapy in Sweden. MethodsData were extracted from Swedish registers and medical records on 433 women, 18-60 years of age, diagnosed 1998-2002 with lymph node-positive BC, and considered for adjuvant chemotherapy. CTR-CVT was defined as HT, CAD, HF, or AF after the diagnosis of BC. Follow-up was from the date of BC diagnosis until November 30, 2021, or death. Prevalence of CTR-CVT and all-cause mortality were calculated. Hazard ratios (HR) were determined for factors associated with CTR-CVT. ResultsThe median age was 50 (interquartile range (IQR) 32) years. 910 CTR-CVT events were diagnosed in 311 women with a median of 19.3 (IQR 15,3) years follow-up. The proportions of CTR-CVT events were: HT 281 (64%); CAD 198 (46%); HF 206 (47%); and AF 225 (51%). The cumulative incidence of CTR-CVT was 71.8%, and 50% of all 433 patients developed CTR-CVT within 11.7 years of BC diagnosis (standard deviation (SD) 0.57, 95% confidence interval (CI) 10.6-12.9). Age was a risk factor for CTR-CVT. Anthracycline increased the risk for HF (p=0,001; HR 2,0; 95%CI 1,4-2,8), CAD (p= 0,002; HR 1,7; 95% CI 1,2-2,4), and AF (p=0,013; HR 1,5; 95% CI 1,0-2,0). At the end of the 24-year study period, 227 of the 433 women were alive, and the total cumulative mortality was 47,6%. ConclusionThe prevalence of CTR-CVT and all-cause mortality is high after BC diagnosis and treatment, particularly in older patients and those receiving anthracyclines. These findings and the onset of CTR-CVT support cardio-oncology guidelines recommending initial risk stratification and cardiovascular monitoring during treatment, followed by long-term annual screening for cardiovascular risk factors and CTR-CVT among BC survivors.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Mallios, PanagiotisLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken i Norrköping(Swepub:liu)n/a
(författare)
-
Karlström, PatricLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Ryhov Cty Hosp, Sweden(Swepub:liu)patka84
(författare)
-
Papakonstantinou, AndriKarolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden; Comprehens Canc Ctr, Sweden
(författare)
-
Bergh, JonasKarolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden; Comprehens Canc Ctr, Sweden
(författare)
-
Hedayati, ElhamKarolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden; Comprehens Canc Ctr, Sweden
(författare)
-
Linköpings universitetAvdelningen för diagnostik och specialistmedicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Frontiers in Oncology: FRONTIERS MEDIA SA442234-943X
-
Ingår i:EUROPEAN HEART JOURNAL: FRONTIERS MEDIA SA440195-668X
Internetlänk
Hitta via bibliotek
Till lärosätets databas